Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Rab 32 Gene Polymorphisms as a Prognostic Factor in Leprosy Patients and Its Relation to Multiple Drug Therapy: Randomized Clinical Trial

NCT06819449 is registered in ClinicalTrials.gov with South Valley University as lead sponsor.

NCT NCT06819449
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06819449 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Rab 32 Gene Polymorphisms as a Prognostic Factor in Leprosy Patients and Its Relation to Multiple Drug Therapy: Randomized Clinical Trial
Lead sponsor
South Valley University
Phase
Not applicable
Overall status
Recruiting
Start date
December 20, 2024
Completion date
December 20, 2025
Enrollment
50 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

leprosy, mycobacterium leprae infection